These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17584107)

  • 21. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
    Dimmeler S; Aicher A; Vasa M; Mildner-Rihm C; Adler K; Tiemann M; Rütten H; Fichtlscherer S; Martin H; Zeiher AM
    J Clin Invest; 2001 Aug; 108(3):391-7. PubMed ID: 11489932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
    Beckman JA; Liao JK; Hurley S; Garrett LA; Chui D; Mitra D; Creager MA
    Circ Res; 2004 Jul; 95(2):217-23. PubMed ID: 15178637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins.
    Brouet A; Sonveaux P; Dessy C; Moniotte S; Balligand JL; Feron O
    Circ Res; 2001 Nov; 89(10):866-73. PubMed ID: 11701613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidative effects of statins.
    Adam O; Laufs U
    Arch Toxicol; 2008 Dec; 82(12):885-92. PubMed ID: 18670762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N
    J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of statins on endothelium, inflammation and cardioprotection.
    Elrod JW; Lefer DJ
    Drug News Perspect; 2005 May; 18(4):229-36. PubMed ID: 16034478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins and endothelial dysfunction.
    Larose E; Ganz P
    Semin Vasc Med; 2004 Nov; 4(4):333-46. PubMed ID: 15861315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the molecular mechanisms of statins in regulating endothelial nitric oxide bioavailability: Interlocking biology between eNOS activity and L-arginine metabolism.
    Chen WH; Chen CH; Hsu MC; Chang RW; Wang CH; Lee TS
    Biomed Pharmacother; 2024 Feb; 171():116192. PubMed ID: 38262153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
    Haendeler J; Hoffmann J; Zeiher AM; Dimmeler S
    Circulation; 2004 Aug; 110(7):856-61. PubMed ID: 15289372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.
    Urbich C; Dimmeler S
    Kidney Int; 2005 May; 67(5):1672-6. PubMed ID: 15840010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statin therapy and angiogenesis.
    Skaletz-Rorowski A; Walsh K
    Curr Opin Lipidol; 2003 Dec; 14(6):599-603. PubMed ID: 14624137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simvastatin restores pulmonary endothelial function in the setting of pulmonary over-circulation.
    Boehme JT; Sun X; Lu Q; Barton J; Wu X; Gong W; Raff GW; Datar SA; Wang T; Fineman JR; Black SM
    Nitric Oxide; 2024 Jan; 142():58-68. PubMed ID: 38061411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin.
    Kalinowski L; Dobrucki LW; Brovkovych V; Malinski T
    Circulation; 2002 Feb; 105(8):933-8. PubMed ID: 11864921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-density lipoprotein-cholesterol-induced endothelial dysfunction and oxidative stress: the role of statins.
    Hermida N; Balligand JL
    Antioxid Redox Signal; 2014 Mar; 20(8):1216-37. PubMed ID: 23924077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.
    Margaritis M; Channon KM; Antoniades C
    Antioxid Redox Signal; 2014 Mar; 20(8):1198-215. PubMed ID: 24111702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simvastatin ameliorates angiotensin II-induced endothelial dysfunction through restoration of Rho-BH4-eNOS-NO pathway.
    Zhang Z; Wang M; Xue SJ; Liu DH; Tang YB
    Cardiovasc Drugs Ther; 2012 Feb; 26(1):31-40. PubMed ID: 22083280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities.
    Kietadisorn R; Juni RP; Moens AL
    Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E481-95. PubMed ID: 22167522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of endothelial dysfunction in atherosclerosis.
    Davignon J; Ganz P
    Circulation; 2004 Jun; 109(23 Suppl 1):III27-32. PubMed ID: 15198963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation.
    Gelosa P; Cimino M; Pignieri A; Tremoli E; Guerrini U; Sironi L
    Vasc Health Risk Manag; 2007; 3(5):567-77. PubMed ID: 18078008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.